Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
December 5th, 2017
12.2K views
Heterogeneous distribution of HER2-positive cells can be observed in a subset of breast cancers and generates clinical dilemmas. Here, we introduce a reliable and cost-effective protocol to define, quantify, and compare HER2 intra-tumor genetic heterogeneity in a large series of heterogeneously processed breast cancers.
Overview
This article presents a reliable and cost-effective protocol for defining, quantifying, and comparing HER2 intra-tumor genetic heterogeneity in breast cancers. The method utilizes high-throughput silver in situ hybridization to address clinical dilemmas arising from the heterogeneous distribution of HER2-positive cells.
Key Study Components
Area of Science
- Breast Cancer Research
- Genetic Heterogeneity
- In Situ Hybridization Techniques
Background
- HER2-positive cells exhibit heterogeneous distribution in some breast cancers.
- This heterogeneity poses challenges for clinical decision-making.
- Existing methods may struggle with archival samples due to varied processing.
- High-throughput techniques can enhance analysis across multiple samples.
Purpose of Study
- To develop a method for analyzing HER2 gene amplification heterogeneity.
- To facilitate research on breast cancer using a large cohort from pathology archives.
- To improve the reliability of HER2 analysis in clinical settings.
Methods Used
- High-throughput silver in situ hybridization.
- Analysis of a large series of breast cancer cases.
- Comparison of HER2 genetic heterogeneity across different tumor areas.
- Utilization of archival samples with varied fixation and processing.
Main Results
- The method allows for effective quantification of HER2 heterogeneity.
- High-throughput analysis reveals significant variations in HER2 expression.
- Results can inform treatment decisions in breast cancer management.
- The protocol is adaptable for various processing conditions of samples.
Conclusions
- This protocol enhances the understanding of HER2 heterogeneity in breast cancer.
- It provides a valuable tool for researchers and clinicians alike.
- Future studies can build on this method to further investigate HER2-related therapies.
Frequently Asked Questions
What is HER2 genetic heterogeneity?
HER2 genetic heterogeneity refers to the variation in HER2 expression levels within different areas of a tumor, which can impact treatment outcomes.
How does high-throughput silver in situ hybridization work?
This technique allows for the simultaneous analysis of multiple samples, enabling researchers to assess HER2 expression across various tumor regions efficiently.
Why is it important to study HER2 heterogeneity?
Understanding HER2 heterogeneity is crucial for tailoring effective treatments and improving patient outcomes in breast cancer therapy.
What challenges do archival samples present?
Archival samples may have undergone different fixation and processing methods, complicating the analysis of genetic markers like HER2.
Who conducted this study?
The study was conducted by a team at an institutional laboratory, with Giulia Ercoli demonstrating the procedure.
Can this method be applied to other cancers?
While this study focuses on breast cancer, the methodology may be adaptable for investigating HER2 in other cancer types.
Executive Industry Relevance
HER2 heterogeneity in breast cancer complicates treatment decisions and contributes to variable clinical outcomes, creating a need for standardized, scalable assessment methods. This high-throughput SISH platform enables simultaneous quantification of HER2 gene amplification across multiple tumor topographies and archival samples, supporting preclinical target validation and biomarker stratification. By providing reproducible, quantitative HER2 status mapping, the method enhances predictive confidence in early discovery and translational research workflows.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of HER2 amplification patterns across tumor regions to clarify target validity and biological relevance.
- Operational Value: Supports functional target de-risking by quantifying intra-tumor genetic variability in archival breast cancer cohorts.
- Predictive Value: Generates HER2/chromosome 17 signal ratios and copy number thresholds to inform go/no-go decisions in target selection.
Screening & Assay Development
- Assay Readiness: Produces standardized TMA formats optimized for SISH, enabling scalable screening of HER2 status across heterogeneous samples.
- Quantitative Output: Delivers HER2/chromosome 17 ratio and average HER2 copy number per cell as measurable endpoints for assay validation.
- Platform Reuse: Adaptable to other cancer types (e.g., gastric) where HER2 heterogeneity impacts therapeutic response, supporting cross-indication assay portability.
Translational & Preclinical Research
- Translational Continuity: Maps HER2 status from discovery through preclinical models by preserving spatial heterogeneity in FFPE tissues.
- Biomarker Alignment: Integrates with IHC for ER, PR, Ki67, and HER2 to enable multimodal biomarker profiling in archival cohorts.
- Risk-Adjusted Advancement: Identifies HER2-negative subpopulations within ostensibly HER2-positive tumors, informing combination therapy strategies and resistance mechanisms.
Pipeline & Workflow Integration
The method fits within the discovery-to-translational continuum, enabling HER2 heterogeneity assessment after target identification and before preclinical efficacy testing, particularly in biomarker-driven stratification.
- Discovery Biology: Facilitates hypothesis testing on HER2 amplification patterns and pathway heterogeneity in primary tumor samples.
- Screening: Ensures assay reproducibility through standardized TMA construction and SISH protocol execution across variably processed specimens.
- Analytics: Provides quantitative HER2/chromosome 17 ratios and copy number thresholds to enable objective comparison of genetic heterogeneity.
- Translational Research: Supports continuity to preclinical work by linking spatial HER2 patterns to functional outcomes in model systems.
- Enterprise Reuse: Establishes a scalable, standardized platform for HER2 assessment applicable across multiple cancer indications and archival sample sets.
Operational & Enterprise Impact
- Scientific Value: Reduces mechanistic ambiguity in HER2-driven pathways by resolving intra-tumor genetic heterogeneity.
- Operational Value: Ensures standardization and reproducibility through automated TMA arraying and optimized SISH conditions.
- Strategic Value: Improves go/no-go decision efficiency by providing quantitative HER2 thresholds for patient stratification in preclinical studies.
- Portfolio Impact: Enables risk-adjusted prioritization of HER2-targeted candidates by identifying tumors with heterogeneous amplification profiles.
Implementation Considerations
- Requires expertise in tissue microarray construction, in situ hybridization, and digital pathology analysis.
- Dependent on automated stainers, TMA arrayers, and imaging systems capable of SISH signal detection.
- Necessitates cross-team standardization between pathology, molecular biology, and bioinformatics for consistent data interpretation.
- Must account for variations in fixation, processing, and storage when comparing HER2 signals across archival samples.
- Limited to DNA-level HER2 amplification assessment; does not capture protein expression or signaling activity without complementary IHC or functional assays.
Biopharma FAQs
Why does HER2 chromosome 17 ratio matter for target validation?
The HER2/chromosome 17 ratio distinguishes true gene amplification from polysomy, ensuring that only tumors with genuine HER2 amplification are selected for targeted therapy development, which improves target confidence and reduces false-positive leads in discovery pipelines.
How does isolating HER2 signals from chromosome 17 probes support discovery pipeline decisions?
By separately quantifying HER2 and chromosome 17 signals, the method enables calculation of amplification ratios that clarify whether observed HER2 gains are due to focal amplification or chromosomal instability, directly informing target validity and mechanistic de-risking in early-stage programs.
What quantitative HER2 measurements enable preclinical go/no-go decisions?
Assessing HER2 amplification requires both a HER2/chromosome 17 ratio ≥2.0 and an average HER2 copy number ≥4.0 signals per cell; these dual thresholds provide objective, reproducible criteria for defining HER2-positive status in heterogeneous tumors, supporting biomarker-stratified study designs.
Why are replication requirements critical for cross-functional collaboration in HER2 studies?
Replication across multiple tumor areas and cases ensures that observed HER2 heterogeneity is not due to technical artifacts, enabling reliable data sharing between discovery, translational, and clinical teams and strengthening confidence in biomarker-defined subgroups.
What statistical analysis is required before implementing HER2 SISH in screening workflows?
Implementation requires statistical validation of HER2/chromosome 17 ratios and copy number distributions across TMA spots to establish assay sensitivity, specificity, and cutoff reproducibility, ensuring that the platform can reliably detect true heterogeneity versus noise in large-scale screening campaigns.
Chapters in this video
0:05
Title
1:24
Design and Construct Tissue Microarrays (TMAs) Based on the Kononen Technique
6:20
Silver In Situ Hybridization (SISH) Analysis of Human Epidermal Growth Factor Receptor 2 (HER2)
9:11
Results: Analysis of Heterogeneity of HER2 Gene Amplification in Breast Cancers
10:00
Conclusion
